Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised Ascendis Pharma’s price target to $315 from $300 and maintained an “overweight” rating, implying 17.95% upside from the prior close.
• Analyst sentiment is broadly positive: 19 analysts rate the stock Buy and two Hold, with a consensus “Moderate Buy” rating and an average target of $306.25.
• Ascendis reported third-quarter product revenue of €366 million, up 89% year over year, led by €291 million in YORVIPATH revenue; it also expects at least €600 million in full-year operating cash flow.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $300.00 to $315.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. Cantor Fitzgerald's price objective would indicate a potential upside of 17.95% from the stock's previous close.

ASND has been the topic of a number of other reports. Oppenheimer lifted their price target on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an "outperform" rating in a research note on Tuesday, September 1st. TD Cowen reaffirmed a "buy" rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. BMO Capital Markets reiterated an "outperform" rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Morgan Stanley cut their target price on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 1st. Finally, Jefferies Financial Group cut their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a "buy" rating on the stock in a research report on Monday, August 31st. Nineteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $306.25.

Ascendis Pharma A/S Trading Up 3.0%

NASDAQ ASND opened at $267.07 on Friday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a twelve month low of $188.07 and a twelve month high of $282.15. The company has a market cap of $16.66 billion, a price-to-earnings ratio of 20.72 and a beta of 0.40. The business's fifty day moving average is $242.58 and its 200 day moving average is $239.65.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Insider Activity at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 40.00% of the company's stock.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP raised its holdings in Ascendis Pharma A/S by 435.8% during the 3rd quarter. First Trust Advisors LP now owns 86,940 shares of the biotechnology company's stock worth $19,807,000 after purchasing an additional 70,714 shares during the last quarter. Allianz SE increased its position in shares of Ascendis Pharma A/S by 219.4% during the third quarter. Allianz SE now owns 16,215 shares of the biotechnology company's stock worth $3,694,000 after buying an additional 11,138 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $6,075,000. GW&K Investment Management LLC raised its stake in Ascendis Pharma A/S by 121.2% during the third quarter. GW&K Investment Management LLC now owns 564 shares of the biotechnology company's stock worth $128,000 after buying an additional 309 shares during the last quarter. Finally, USS Investment Management Ltd raised its position in shares of Ascendis Pharma A/S by 21.0% in the 3rd quarter. USS Investment Management Ltd now owns 170,587 shares of the biotechnology company's stock worth $38,878,000 after acquiring an additional 29,577 shares in the last quarter.

Ascendis Pharma A/S News Roundup

Investors following ASND have been watching these news items:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.